Key result
Acorn Cardiac Support Device improves mean LVEF by ~11 points at 6 months in heart failure.
Answers are grounded in this paper and cite their sources.
Safety and feasibility study shows a textile cardiac support device improves ventricular function and symptoms in chronic heart failure, indicating potential for reverse remodeling.
Background Progressive remodeling and dilation of cardiac chambers is responsible in part for myocardial dysfunction in chronic heart failure. Preclinical studies with suitable animal models indicate that a passive cardiac constraint device can promote reverse remodeling, with improvement in cardiac function. We hypothesize that such a device could provide benefit for stable heart failure patients in New York Heart Association (NYHA) class II and III . Methods and Results From April 1999 to March 2000, 27 patients received Acorn’s Cardiac Support Device (CSD) during an initial safety/feasibility study. In 11 patients, the only surgical measure was CSD placement. Most patients suffered from idiopathic cardiomyopathy; 4 were in NYHA class II, one was in class II/III, and 6 were in class III. All were stable on intensive medical treatment. The CSD, a textile polyester device, was fitted snugly around the heart during surgery. All patients survived surgery and recovered smoothly. Three months after surgery, 56% of patients were in NYHA class I, 33% were in class II, and 11% were in class II/III. Echocardiography showed an improvement in left ventricular ejection fraction from an average of 22% to 28% and 33% at 3 and 6 months, respectively. Simultaneously, the left ventricular end-diastolic dimension decreased from 74 mm to 68 mm and 65 mm, respectively. Mitral valve regurgitation (on a scale of 0 to 4+) decreased from 1.3 to 0.7 by 3 months. Quality-of-life indices correlated with the apparent reversal of ventricular remodeling. Preoperative cardiac medications remained virtually unchanged after implant. Conclusions In the short- and intermediate-term, CSD implantation seems to ameliorate symptoms and improve cardiac and functional performance in heart failure patients. Worldwide randomized trials are currently underway.
No takes yet. Share an insight, caveat, or question.
Konertz et al. (2001) studied Chronic heart failure (predominantly idiopathic cardiomyopathy) (n=27). Acorn Cardiac Support Device (CSD) implantation was evaluated on Left ventricular ejection fraction (LVEF) and ventricular remodeling at 3 and 6 months. Acorn Cardiac Support Device implantation improved mean LVEF from 22% to 33% and reduced LVEDD from 74 mm to 65 mm at 6 months in stable functional class II-III heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: